Editas Medicine Reports Positive EDIT-401 Preclinical Data and Outlines 2026 Clinical Trial Plans

Editas Medicine announced new preclinical data for EDIT-401, its lead in vivo gene editing candidate, at the 94th European Atherosclerosis Society (EAS) Congress. In non-human primate (NHP) studies, a single dose of EDIT-401 achieved approximately 90% mean reductions in LDL-C, Lp(a), and ApoB. These reductions were rapid, dose-dependent, and durable through six months. Interim results from an ongoing GLP toxicology study in NHPs indicated that EDIT-401 was well-tolerated at the therapeutically relevant dose of 1.5 mg/kg, with no adverse clinical observations or liver enzyme elevations. The company received positive pre-IND feedback from the FDA and plans to submit a Clinical Trial Notification (CTN) in Australia by mid-2026. Editas aims to initiate a Phase 1/2 first-in-human clinical trial in patients with Heterozygous Familial Hypercholesterolemia (HeFH) later in 2026. The company expects to report early in vivo human proof-of-concept data by the end of 2026 and topline data from the Phase 1/2 study in 2027.